Literature DB >> 17362463

Erythropoietin levels in aqueous humour in eyes with exudative age-related macular degeneration and diabetic retinopathy.

Jost B Jonas, Michael Neumaier.   

Abstract

The purpose of this study was to evaluate whether the concentration of erythropoietin as another potent ischemia-induced angiogenic factor is elevated in eyes with neovascular (age-related macular degeneration [AMD]) or oedematous (diabetic retinopathy) maculopathies. The clinical comparative study included 28 patients with diabetic macular oedema, 59 patients with exudative AMD, and 49 patients with cataract. For all patients, aqueous humour was collected during cataract surgery or during an intravitreal injection of triamcinolone acetonide. Erythropoietin levels were measured using a solid-phase chemiluminescence immunoassay. The mean concentration of erythropoietin was significantly higher in the diabetic group (60.1 +/- 46.7 mUnits/mL; P < 0.001) than in the age-related macular degeneration group (22.9 +/- 23.2 mUnits/mL) and in the control group (22.0 +/- 21.0 mUnits/mL; P < 0.001). The two latter groups did not vary significantly (P = 0.41). The results indicate that erythropoietin may be present in considerably higher concentrations in eyes with diabetic macular oedema than in eyes with exudative AMD or normal eyes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17362463     DOI: 10.1111/j.1442-9071.2006.01437.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  11 in total

1.  Aqueous humor and serum erythropoietin levels in patients with pseudoexfoliation syndrome and pseudoexfoliative glaucoma.

Authors:  Başak Doğu; Nurşen Yüksel; Mustafa Baki Cekmen; Yusuf Cağlar
Journal:  Int Ophthalmol       Date:  2010-09-23       Impact factor: 2.031

2.  Combination of intravitreal bevacizumab and erythropoietin versus intravitreal bevacizumab alone for refractory diabetic macular edema: a randomized double-blind clinical trial.

Authors:  Morteza Entezari; Zahra Kiani Flavarjani; Alireza Ramezani; Humayon Nikkhah; Saeed Karimi; Hamid Fateh Moghadam; Narsis Daftarian; Mehdi Yaseri
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-08-10       Impact factor: 3.117

3.  Effect of vitrectomy on macular microcirculation in patients with diffuse diabetic macular edema.

Authors:  Jung Hyun Park; Se Joon Woo; Youn Jin Ha; Hyeong Gon Yu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-03-18       Impact factor: 3.117

4.  Current and future approaches in the prevention and treatment of diabetic retinopathy.

Authors:  Louis K Chang; David Sarraf
Journal:  Clin Ophthalmol       Date:  2008-06

Review 5.  Revisiting the role of erythropoietin for treatment of ocular disorders.

Authors:  S L Shirley Ding; S N Leow; R Munisvaradass; E H Koh; M L C Bastion; K Y Then; S Kumar; P L Mok
Journal:  Eye (Lond)       Date:  2016-06-10       Impact factor: 3.775

6.  Diabetic retinopathy risk factors: plasma erythropoietin as a risk factor for proliferative diabetic retinopathy.

Authors:  Yaghoobi Gholamhossein; Heydari Behrouz; Zarban Asghar
Journal:  Korean J Ophthalmol       Date:  2014-09-18

Review 7.  Erythropoietin in ophthalmology: A literature review.

Authors:  Kaveh Abri Aghdam; Mostafa Soltan Sanjari; Khalil Ghasemi Falavarjani
Journal:  J Curr Ophthalmol       Date:  2016-03-30

8.  Association between macular degeneration and mild to moderate chronic kidney disease: A nationwide population-based study.

Authors:  Chun-Yu Chen; Ciou-Sia Dai; Chin-Chan Lee; Yu-Chiau Shyu; Ting-Shuo Huang; Ling Yeung; Chi-Chin Sun; Huang-Yu Yang; I-Wen Wu
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

Review 9.  Aqueous humour concentrations of PEDF and Erythropoietin are not influenced by subthreshold micropulse laser treatment of diabetic macular edema.

Authors:  Edoardo Midena; Silvia Bini; Luisa Frizziero; Elisabetta Pilotto; Graziana Esposito; Alessandra Micera
Journal:  Biosci Rep       Date:  2019-06-18       Impact factor: 3.840

10.  Erythropoietin Gene Therapy Delays Retinal Degeneration Resulting from Oxidative Stress in the Retinal Pigment Epithelium.

Authors:  Manas R Biswal; Zhaoyao Wang; Ryan J Paulson; Rukshana R Uddin; Yao Tong; Ping Zhu; Hong Li; Alfred S Lewin
Journal:  Antioxidants (Basel)       Date:  2021-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.